Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Dolocam Plus** is an oral fixed-dose combination of **meloxicam** and **methocarbamol** manufactured by Representaciones e Investigaciones Médicas. Meloxicam is an oxicam nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase-mediated prostaglandin synthesis, with relative preference for cyclooxygenase-2. Methocarbamol is a centrally acting skeletal muscle relaxant thought to reduce muscle spasm through generalized central nervous system depressant effects. The product is supplied as capsules containing either 7.5 mg or 15 mg meloxicam plus 215 mg methocarbamol and is indicated for painful musculoskeletal conditions accompanied by inflammation, muscle spasm, and restricted mobility, including traumatic injuries, muscle strains, torticollis, bursitis, arthritis, tendinitis, and muscle contractures.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on meloxicam + methocarbamol.